BAYNE, Wash.

— As a woman with endometriotic disease, Barbara Boon is in a bit of a quandary.

The 58-year-old retired nursing home administrator has been told she has to wait three years to have her cancer treated, with no indication of when she will be able to see a doctor.

And with an endometrial cancer, she’s not sure she’ll be able find a specialist she can see for the next three years.

The treatment that Boon needs is called endometrionavir treatment.

It involves injections of a drug that is injected into the lining of the uterus to prevent infection, and can also be administered to help stop the bleeding in the pelvic region.

“It’s the only treatment I’ve had that works,” Boon said, speaking through a translator.

“It’s been a roller coaster, but I’ve been able to get through it.”

Boon is among the nearly 400,000 women in the United States treated with a stem cell therapy that has been linked to a reduced risk of endometrium cancer, and is also used to treat uterine fibroids and uterine pain.

But the treatment is also causing concern for some women who say it has caused more side effects than it has helped, and that it is now causing them to suffer more pain and suffering.

In April, the American College of Obstetricians and Gynecologists issued a report saying that while endometrolib use was associated with a reduction in the risk of uterine cancer, it was not yet clear whether the treatment reduced the risk or simply increased the likelihood of complications.

A review of research published in April in the American Journal of Obstetrics and Gynaecology found that the drug is not 100 percent effective for treating uterine cancers, and in some cases, patients had higher than expected cancer rates.

Despite that, Boon has been assured she has a chance of receiving the treatment, but her doctor told her she has three years of treatment left to wait.

That means that in the coming years, her doctors will continue to prescribe her the drug, and she will have to continue to endure more pain, suffering and discomfort, according to her attorney, Scott T. Smith.

Even if her doctor were to recommend that she get the treatment now, she would not have the time to do it, she said.

The problem is that Bonta, the mother of four, is living with a severe chronic illness that will be with her for the rest of her life.

For Bontas husband, it’s the constant pain that keeps him up at night.

He says the pain, which is usually relieved by medication, makes him feel suicidal.

I’ve got a doctor that says we don’t have a choice.

I’ve got to take it or else, I’m going to end up like this, said Bonto, who has two sons and four grandchildren.

He’s also struggling to find a way to cope with the constant anxiety and pain, and said that he is having trouble sleeping, despite having a job and a mortgage.

Bonta’s pain, he said, is something that can’t be ignored.

If the government doesn’t act now, he worries, she will end up on the streets, like her husband.

Smith, who is representing Bontos, said that while it’s possible that the treatment Bontais needs could be available by the end of this year, it is too soon to predict.

Treatments are being made to more than 2 million women worldwide, and there are hopes that there could be another 100,000 in the U.S. by the time the U and Canada begin trials later this year.

With endometritis being the most common cause of cancer in the developing world, there are about 2.2 million cases in the country, and the U., which has the world’s largest uterus, has more than two-thirds of the world population, Smith said.

There is a long way to go, and Bontaras situation has not improved, he added.

We need a better way of treating endometria and uterines.

It is a very serious condition and we need to get this right.

Read or Share this story: http://usat.ly/1b9X6aN